M&AHealthcareSIGNED
Telix Pharmaceuticals to acquire and merge with BlackRock-backed ITM for up to $2.35bn
Value
$2.4Bn
Acquirer
Telix Pharmaceuticals
Target
ITM
Telix Pharmaceuticals is set to acquire and merge with ITM, a company backed by BlackRock, in a deal valued at up to $2.35 billion. Telix will pay an upfront cash sum of $1.65 billion for 100 percent of ITM's shares, with an additional $700 million in contingency payments.
✦ Meridian Analysis
This headline describes a significant M&A transaction in the healthcare sector, involving a pharmaceutical company acquiring a BlackRock-backed entity. The deal structure includes both an upfront cash payment and contingent payments, reflecting a common approach in larger acquisitions.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.